Immunotherapy of pancreatic cancer with triptolide combined with ginsenoside Rg3
10.16438/j.0513-4870.2023-0858
- VernacularTitle:雷公藤甲素联合人参皂苷Rg3免疫治疗胰腺癌研究
- Author:
Wen-wen ZHAO
1
;
Ting-ting JIANG
1
;
Zhi-rong WANG
2
;
Yun-yun WANG
2
;
Xiang-xiang WU
2
;
Hua-hui ZENG
2
Author Information
1. College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
2. College of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
- Publication Type:Research Article
- Keywords:
liposome;
triptolide;
ginsenoside Rg3;
pancreatic cancer;
immunotherapy;
T cell
- From:
Acta Pharmaceutica Sinica
2024;59(6):1794-1803
- CountryChina
- Language:Chinese
-
Abstract:
Liposome was used as carrier to carry triptolide and ginsenoside Rg3 in the treatment of pancreatic cancer tumor mice. The effects of liposome on the levels of CD4+ and CD8+ microenvironmental immune factors of pancreatic cancer tumor were investigated, and the tumor inhibitory effect and safety were evaluated. In this study, Pan02 cells were used to construct a tumor-bearing C57BL/6 mouse model. After 14 days of treatment, the changes in tumor volume and body weight of tumor-bearing mice were observed. The results showed that the high and low doses of liposome had significant therapeutic effect on tumor volume in the model group (P < 0.01), and the tumor inhibition rate of high doses of liposome was significantly increased compared with triptolide group (P < 0.05). Immunohistochemistry showed that compared with the model group, the tumor inhibition rate of liposome was significantly increased. The high-dose liposome group can up-regulate the ratio of immune factor CD4+/CD8+, inhibit the expression of tumor proliferation factor and promote the expression of tumor apoptosis factor, and has a high safety after pathological hematoxylin and eosin staining of liver, spleen, lung and kidney and serum factor detection. Animal welfare and experimental procedures are in accordance with the regulations of the Experimental Animal Ethics Committee of Henan University of Chinese Medicine (approval No.: DWLL202103173). This study provides a new idea for the exploration of immunotherapy for pancreatic cancer.
